goal therapeutic services, inc.

8532 56th avenue
2nd floor
elmhurst, new york 11373

NYS Entity Status
ACTIVE

NYS Filing Date
NOVEMBER 07, 2013

NYS DOS ID#
4483876

County
QUEENS

Jurisdiction
NEW YORK

Registered Agent
NONE

NYS Entity Type
DOMESTIC BUSINESS CORPORATION

Name History
2013 - GOAL THERAPEUTIC SERVICES, INC.









Buffer



submit to reddit

Telephone
n/a

Fax
n/a

Website
n/a

Email address
n/a

LinkedIn
n/a

Facebook
n/a

Google+
n/a

Twitter
n/a

Pinterest
n/a

Instagram
n/a



  • AROUND THE WEB

  • FDA Refuses to Review Acorda Parkinson’s Drug, Shares Tumble
    By Ben Fidler - Tuesday Aug 29, 2017

    The heat is on Acorda Therapeutics once again. Months after Acorda lost a key group of patents, the FDA has declined to review, at least for now, an experimental Parkinson’s disease drug that is critical to the company’s future. Acorda (NASDAQ: ACOR) said this morning that the FDA has sent the Ardsley, NY, company a […]

    Source: Xconomy New York
  • Publisher Tronc acquires Daily News, storied NY tabloid
    By JENNIFER PELTZ, Associated Press - Monday Sep 4, 2017

    NEW YORK (AP) — Newspaper publisher Tronc has acquired the Daily News, a storied New York tabloid newspaper that won a Pulitzer Prize this year but has been buffeted by the changing media environment.Chicago-based Tronc Inc., the publisher of the Los Angeles Times and the Chicago Tribune, announced the deal Monday night, and the Daily News posted a story on its website.Tronc CEO Justin Dearborn said acquiring the paper and its popular website would "provide us with another strategic platform for growing our digital business, expanding our reach and broadening our services for advertisers and marketers," and both Tronc and Daily News executives said the company would maintain the quality of the paper's journalism.

    Source: SFGATE.com: Top News Stories
  • For Parkinson’s, Two New Drugs Coming As Prevail Gets Started in NY
    By Ben Fidler - Wednesday Aug 9, 2017

    A drug that actually slows or reverses the brain damage inflicted by Parkinson’s disease, rather than just alleviates its often debilitating symptoms, remains elusive. But Prevail Therapeutics, a startup just launched in New York, has become the latest to try. This morning, the Silverstein Foundation, a nonprofit organization formed by OrbiMed partner Jonathan Silverstein, announced […]

    Source: Xconomy New York
  • Insurers Battle Families Over Costly Drug for Fatal Disease
    By KATIE THOMAS - Thursday Jun 22, 2017

    The case of Exondys 51 poses emotionally charged issues for families of young boys with a rare illness, who are fighting companies to get coverage for an expensive drug approved on a lower bar of proof.

    Source: NYT > Home Page
  • “It’s Shame On Us If We Blow It”: Highlights From NY Seizes the Momentum
    By Ben Fidler - Wednesday Jun 7, 2017

    Mike Foley, a drug industry veteran and director of the Tri-Institutional Therapeutics Discovery Institute, has a pointed message for the New York life sciences industry: Don’t waste the moment. Changing the course of New York biotech has been a saga that dates back to the 1990s, and as Xconomy has detailed, progress has been made […]

    Source: Xconomy New York
goal therapeutic services inc elmhurst ny